REGENXBIO, Inc. (RGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.94-2.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Resolve FDA rejection of RGX-121 and GSK sublicense dispute: FDA hold active vs resolved by end 2026.
Regenxbio has a $150 million cash balance to fund operations into 2027. It earned a $100 million milestone payment from AbbVie. The company is working to resolve FDA and GSK regulatory issues. These steps could help it recover and grow.
Regenxbio is losing money and faces regulatory setbacks. Revenue is expected to fall about 60% next year. Cash runway concerns could limit operations. These problems may delay recovery or cause further losses.
The stock trades about 30% below our fair value near $21. Analysts expect revenue to drop 60% next year. The market prices in a tough near-term outlook but may not fully reflect recovery potential.
Breaks if: cash balance falls below $100 million before early 2027
Breaks if: FDA rejection or GSK dispute unresolved past 2026
Revenue decline exceeds 10% YoY in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. RGNX is focused on advancing gene therapies, which could yield significant returns if successful, but it faces high risks and is currently loss-making.
The market appears to be pricing in a low expectations gap, indicating that RGNX is seen as cheap compared to its peers. However, there is a divergence in valuation, with a slight premium over some competitors, suggesting cautious optimism.
Management has shown stability and strong recent financial performance, particularly with the RGX-202 gene therapy. However, the company remains loss-making, and there is a notable risk of missing future earnings expectations.
The long-term thesis hinges on the successful advancement of RGX-202 and sura-vec, as well as the resolution of regulatory issues. Additionally, external factors such as sector performance and economic conditions will play a crucial role.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Our read has weakened. It is challenged by rgnx: a sharp drop may be repricing the thesis. It is supported by the latest earnings beat.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, RGNX's trajectory will depend on its ability to execute on its clinical priorities and navigate market risks. Not investment advice.